We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
-0.39%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.25B
AUM Growth
-$167M
(-6.9%)
Cap. Flow
-$1.74M
Cap. Flow
% of AUM
-0.08%
Top 10 Holdings %
Top 10 Hldgs %
64.56%
Holding
59
New
8
Increased
7
Reduced
14
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
+$90.7M |
| 2 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$53.5M |
| 3 |
OKUR
OnKure Therapeutics
OKUR
|
+$38.3M |
| 4 |
VERV
Verve Therapeutics
VERV
|
+$32.9M |
| 5 |
AbCellera Biologics
ABCL
|
+$11.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Harmony Biosciences
HRMY
|
+$57.4M |
| 2 |
Inogen
INGN
|
+$43M |
| 3 |
Cable One
CABO
|
+$38.6M |
| 4 |
Praxis Precision Medicines
PRAX
|
+$36.6M |
| 5 |
EAR
Eargo, Inc. Common Stock
EAR
|
+$21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.05% |
| 2 | Financials | 7% |
| 3 | Technology | 6.3% |
| 4 | Consumer Discretionary | 2.54% |
| 5 | Communication Services | 2.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total Stock Market ETF
VTI
$656B
| $431M | 19.11% |
1,933,900
| – | – |
|
2
Brookfield
BN
$104B
| $157M | 6.95% |
5,705,809
-32,239
| -0.6% | -$826K |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $152M | 6.73% |
2,645,446
| – | – |
|
4
Apple
AAPL
$4.99T
| $142M | 6.3% |
1,037,404
| – | – |
|
|
5
Inogen
INGN
$174M
| $136M | 6.01% |
2,079,320
-680,000
| -25% | -$43M |
|
6
Edgewise Therapeutics
EWTX
$4.37B
| $119M | 5.29% |
5,587,207
| – | – |
|
|
CYT
7
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $104M | 4.59% |
+4,840,413
| New | +$90.7M |
|
8
Nkarta
NKTX
$161M
| $88.5M | 3.93% |
2,793,864
| – | – |
|
9
Bolt Biotherapeutics
BOLT
$7.78M
| $69.6M | 3.09% |
225,200
| – | – |
|
10
Alibaba
BABA
$277B
| $57.3M | 2.54% |
214,827
| – | – |
|
11
Aligos Therapeutics
ALGS
$26.6M
| $53.3M | 2.36% |
104,583
| – | – |
|
|
SPRB
12
Spruce Biosciences
SPRB
$116M
| $50.6M | 2.24% |
60,191
-6,333
| -10% | -$6.76M |
|
|
13
Cable One
CABO
$244M
| $49.5M | 2.2% |
25,898
-21,443
| -45% | -$38.6M |
|
|
VERV
14
DELISTED
Verve Therapeutics
VERV
| $47.8M | 2.12% |
+793,265
| New | +$32.9M |
|
15
Mirum Pharmaceuticals
MIRM
$6.83B
| $42.3M | 1.88% |
2,445,147
| – | – |
|
|
VECT
16
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $41.1M | 1.82% |
+3,522,019
| New | +$53.5M |
|
|
17
Harmony Biosciences
HRMY
$2.06B
| $40.2M | 1.78% |
1,422,953
-1,913,425
| -57% | -$57.4M |
|
|
LVTX
18
DELISTED
LAVA Therapeutics
LVTX
| $36.2M | 1.61% |
3,327,312
| – | – |
|
|
OKUR
19
OnKure Therapeutics
OKUR
$161M
| $32M | 1.42% |
+343,038
| New | +$38.3M |
|
|
INZY
20
DELISTED
Inozyme Pharma
INZY
| $31.8M | 1.41% |
1,867,706
-101,673
| -5% | -$1.77M |
|
21
Protagonist Therapeutics
PTGX
$8.76B
| $26.9M | 1.19% |
600,010
-267,714
| -31% | -$8.84M |
|
|
GRTX
22
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $24.2M | 1.07% |
2,459,021
| – | – |
|
|
SPNE
23
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $22.8M | 1.01% |
1,113,846
-207,160
| -16% | -$4.26M |
|
24
Insmed
INSM
$22.6B
| $19.8M | 0.88% |
695,840
+239,209
| +52% | +$7.1M |
|
|
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
| $19.3M | 0.85% |
1,997,880
+35,000
| +2% | +$342K |
|
Similar funds
HCA
GX
MP
FLII
CA
IC
WTA
CCA
Novo Holdings A/S's Q2 2021 Portfolio in Review
As of Q2 2021, Novo Holdings A/S held 59 positions worth $2.25B, down 6.9% from $2.42B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Novo Holdings A/S's Q2 2021 filing shows 8 new, 7 increased, 14 reduced and 5 closed positions. Its largest new stake was Cyteir Therapeutics, Inc. Common Stock: 4,840,413 shares worth $104M. The largest sale was Harmony Biosciences, an estimated $57.4M.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 65% a quarter earlier, followed by Financials and Technology.
- Novo Holdings A/S's largest Q2 2021 buy was Cyteir Therapeutics, Inc. Common Stock: 4,840,413 shares worth $104M.
- Novo Holdings A/S added most to Insmed in Q2 2021, an estimated $7.1M increase.
- Novo Holdings A/S's biggest Q2 2021 reduction was Harmony Biosciences, cutting an estimated $57.4M.
- Novo Holdings A/S fully exited Constellation Pharmaceuticals, Inc. in Q2 2021, selling an estimated $16.4M.
- Novo Holdings A/S's ten largest holdings make up 65% of its $2.25B portfolio in Q2 2021.
- Novo Holdings A/S opened 8 new positions and closed 5 in Q2 2021.
- Novo Holdings A/S's portfolio value fell 6.9% quarter-over-quarter to $2.25B.
Based on Novo Holdings A/S's 13F filing for Q2 2021, filed 16 Aug 2021.